Tuesday, March 21, 2023 | Back issues
Courthouse News Service Courthouse News Service

Cancer Drug Antitrust Claims

The Second Circuit ruled that a Russian pharmaceutical firm’s antitrust claims were barred by the Foreign Trade Antitrust Improvements Act, because the alleged price-fixing and kickbacks aimed at thwarting the firm’s U.S. launch of cancer-treatment drugs occurred in Russia. 

NEW YORK – The Second Circuit ruled that a Russian pharmaceutical firm’s antitrust claims were barred by the Foreign Trade Antitrust Improvements Act, because the alleged price-fixing and kickbacks aimed at thwarting the firm’s U.S. launch of cancer-treatment drugs occurred in Russia. 

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading...